低剂量阿米林治疗易怒肠综合征:对患者和全科医生的观点和经验进行定性研究
Emma J Teasdale1, Hazel A Everitt2, Sarah L Alderson3
1Centre for Clinical and Community Applications of Health Psychology, School of Psychology, University of Southampton, Southampton.
概括
低剂量的阿米林在刺激性肠综合征 (IBS) 治疗中提供了潜在的好处,超过了患者和GP对其抗抑郁药物的担忧. 灵活的剂量和额外的好处,如改善睡眠是关键考虑因素.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 定性研究是指质量研究.
背景情况:
- 刺激性肠综合征 (IBS) 显著影响患者的生活质量和医疗资源.
- 低剂量阿米丁氨酸被推作为二线IBS治疗,但在初级保健中未得到充分利用.
研究的目的:
- 调查患者和全科医生 (GP) 关于使用低剂量阿米林治疗IBS的观点.
- 了解处方和使用这种治疗的障碍和促进因素.
主要方法:
- 一项定性研究,涉及英格兰42名患者和16名全科医生的半结构性电话采访.
- 在ATLANTIS试验中随机选择后6个月和12个月收集的数据.
- 应用反思性的专题分析,以确定患者和GP体验中的关键主题.
主要成果:
- 担忧包括阿米特里林的抗抑郁药分类,IBS的潜在医疗化以及副作用.
- 感知到的好处包括灵活的,低剂量管理,易于使用,以及潜在的非IBS症状缓解 (例如,睡眠).
- 患者和全科医生都表达了对新的IBS管理策略的愿望.
结论:
- 试用低剂量阿米林治疗IBS的潜在优势被认为超过了患者和GP的担忧.
- 解决人们对抗抑郁药使用的担忧,并强调灵活的剂量和睡眠益处,可以促进其实施.
- 进一步探索患者和临床医生的经验对于优化IBS管理至关重要.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
01:21Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
228
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
228
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
152
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
152
01:17Assessment of the Gastrointestinal System I: Subjective Data
160
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
160
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
187
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
187